Brief: Lipocine Completes Successful Meeting With FDA On Lpcn 1154 In Postpartum Depression
26/10/2023 13:45
Oct 26 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE COMPLETES SUCCESSFUL MEETING WITH FDA ON LPCN
1154 IN
POSTPARTUM DEPRESSION
* LIPOCINE INC - COMPANY ON TRACK TO INITIATE DOSING IN
PIVOTAL
STUDY Q1'24
Source text for Eikon: ID:nPn77pdXNa
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy